Point-of-care biosensors are critically important for early disease diagnosis and timely clinical intervention in resource-limited settings. The real-world application of these biosensors requires the use of stable biological reagents and cost-effective fabrication approaches. To meet these stringent requirements, we introduce a generic encapsulation strategy to realize ultrastable plasmonic bioink by encapsulating antibodies with an organosiloxane polymer through in situ polymerization. Plasmonic nanostructures serve as sensitive nanotransducers, allowing for label-free biochemical detection. The plasmonic bioink with encapsulated antibodies exhibits excellent thermal, biological, and colloidal stabilities making it compatible with printing process. As a proof-of-concept, we demonstrate the printability of the ultrastable plasmonic bioinks on different types of substrates with direct writing techniques. The organosiloxane polymer preserves the biorecognition capabilities of the biosensors under harsh conditions, including elevated temperature, exposure to chemical/biological denaturants, and ultrasonic agitation. Plasmonic biochips fabricated with the ultrastable ink exhibit superior stability compared to the biochips with unencapsulated antibodies.

The automatic patient positioning system and its alignment is critical and specified to be less than 0.35 mm for a radiosurgical treatment with the latest robotized Gamma Knife Perfexion (GKPFX). In this study, we developed a quantitative QA procedure to verify the accuracy and robustness of such a system. In particular, we applied the test to a unit that has performed >1000 procedures at our institution. For the test, a radiochromic film was first placed inside a spherical film phantom and then irradiated with a sequence of linearly placed shots of equal collimator size (e.g. 4 mm) via the Leksell Gamma Knife Perfexion system (PFX). The shots were positioned with either equal or unequal gaps of approximately 8 mm both at center and off-center positions of the patient positioning system. Two independent methods of localizing the irradiation shot center coordinates were employed to measure the gap spacing between adjacent shots. The measured distance was then compared with the initial preset values for the test. On average, the positioning uncertainty for the PFX delivery system was found to be 0.03 ± 0.2 mm (2σ). No significant difference in the positioning uncertainty was noted among measurements in the x-, y- and z-axis orientations. In conclusion, a simple, fast, and quantitative test was developed and demonstrated for routine QA of the submillimeter PFX patient positioning system. This test also enables independent verification of any patient-specific shot positioning for a critical treatment such as a tumor in the brainstem.

No abstract

No abstract